Vaccine results boost stocks as US biotechnology firm Moderna test positive initial results of the coronavirus disease 2019 (Covid-19) drug.
US biotech firm Moderna said yesterday that its vaccine for COVID-19 appeared to generate an immune response similar to the response seen in people who have been infected by the virus and recovered.
Moderna’s chief medical officer Tal Zaks said: “Interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 μg.”
“The vaccine was generally safe and well tolerated,” Moderna said.
“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralising antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” Zaks added.
The company informed that the Phase-2 trial has already been given the go-ahead by the US Food and Drug Administration(FDA). Moderna said that phase 3 trials with a large number of volunteers would begin in July. More..
Updated: May 20, 2020, StockBytes! PH
*The owner of StockBytes PH is a licensed stock broker, contact us if you want to open an account.
Ready to start your financial journey? email us at [email protected] or follow our social media account and join our groups, Cheers!